KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Retained Earnings (2016 - 2025)

Historic Retained Earnings for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $4.4 billion.

  • West Pharmaceutical Services' Retained Earnings rose 1057.22% to $4.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.4 billion, marking a year-over-year increase of 1057.22%. This contributed to the annual value of $4.4 billion for FY2025, which is 1057.22% up from last year.
  • As of Q4 2025, West Pharmaceutical Services' Retained Earnings stood at $4.4 billion, which was up 1057.22% from $4.3 billion recorded in Q3 2025.
  • West Pharmaceutical Services' 5-year Retained Earnings high stood at $4.4 billion for Q4 2025, and its period low was $2.0 billion during Q1 2021.
  • Moreover, its 5-year median value for Retained Earnings was $3.3 billion (2023), whereas its average is $3.3 billion.
  • Its Retained Earnings has fluctuated over the past 5 years, first soared by 3303.19% in 2021, then surged by 1051.36% in 2025.
  • West Pharmaceutical Services' Retained Earnings (Quarter) stood at $2.5 billion in 2021, then grew by 21.62% to $3.0 billion in 2022, then increased by 17.93% to $3.5 billion in 2023, then grew by 12.29% to $4.0 billion in 2024, then rose by 10.57% to $4.4 billion in 2025.
  • Its last three reported values are $4.4 billion in Q4 2025, $4.3 billion for Q3 2025, and $4.1 billion during Q2 2025.